Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912776918> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2912776918 endingPage "129" @default.
- W2912776918 startingPage "129" @default.
- W2912776918 abstract "129 Background: Nivolumab (Nivo) showed a survival benefit in salvage line of advanced gastric cancer (AGC) patients in ATTRACTION-2 trial. Based on synergistic anti-tumor effects by simultaneous blockade of PD-1 and VEGFR-2, this phase 1/2 study was conducted to investigate the safety and efficacy of Nivo plus ramucirumab (Ram) in the second line chemotherapy for AGC. Methods: AGC patients with measurable lesions, PS 0-1, disease progression on first line chemotherapy containing platinum were eligible. Patients received Nivo (3mg/kg, Q2W) and Ram (8mg/kg, Q2W) until unacceptable toxicity or disease progression. After feasibility was evaluated in six patients (phase 1 part), additional 40 patients were required in a phase 2 part with the primary analysis (expected 6-months progression-free survival (PFS) rate of 36%, threshold of 18%, one-sided alpha level of 10%, power of 90%). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), PFS, overall survival (OS), and safety. Results: 46 AGC patients (median age 66 years, PS 1 40%) were enrolled. No dose limiting toxicities were observed in the phase 1 part. With median follow up time of 10.2 month, 6-month PFS rate was 37.4% (90% confidential intervals: 25.7-49.2%), which met the primary endpoint of the phase 2 part. ORR/DCR were 26.7%/62.2%. Median PFS/OS were 2.9/9.0 months. Among all enrolled patients, grade 3 or 4 treatment related adverse events were hypertension (n = 2), diarrhea (n = 2), perforation at jejunum (n = 1), hemorrhage (n = 1), colitis (n = 1), pancreatitis (n = 1), liver dysfunction (n = 1), cholangitis (n = 1), hematoma (n = 1), neutropenia (n = 1) and proteinuria (n = 1). There were no treatment-related deaths. Conclusions: Combination of Nivo and Ram showed promising antitumor activity and mild toxicity profile for second line AGC, which is worth evaluating in a further confirmatory study. Clinical trial information: NCT02999295." @default.
- W2912776918 created "2019-02-21" @default.
- W2912776918 creator A5008535163 @default.
- W2912776918 creator A5010090426 @default.
- W2912776918 creator A5016744911 @default.
- W2912776918 creator A5026500116 @default.
- W2912776918 creator A5026733873 @default.
- W2912776918 creator A5050468802 @default.
- W2912776918 creator A5055212193 @default.
- W2912776918 creator A5069631984 @default.
- W2912776918 creator A5070444406 @default.
- W2912776918 creator A5070643359 @default.
- W2912776918 creator A5082832235 @default.
- W2912776918 date "2019-02-01" @default.
- W2912776918 modified "2023-09-23" @default.
- W2912776918 title "Phase I/II study of ramucirumab plus nivolumab in patients in second-line treatment for advanced gastric adenocarcinoma (NivoRam study)." @default.
- W2912776918 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.129" @default.
- W2912776918 hasPublicationYear "2019" @default.
- W2912776918 type Work @default.
- W2912776918 sameAs 2912776918 @default.
- W2912776918 citedByCount "31" @default.
- W2912776918 countsByYear W29127769182019 @default.
- W2912776918 countsByYear W29127769182020 @default.
- W2912776918 countsByYear W29127769182021 @default.
- W2912776918 countsByYear W29127769182022 @default.
- W2912776918 countsByYear W29127769182023 @default.
- W2912776918 crossrefType "journal-article" @default.
- W2912776918 hasAuthorship W2912776918A5008535163 @default.
- W2912776918 hasAuthorship W2912776918A5010090426 @default.
- W2912776918 hasAuthorship W2912776918A5016744911 @default.
- W2912776918 hasAuthorship W2912776918A5026500116 @default.
- W2912776918 hasAuthorship W2912776918A5026733873 @default.
- W2912776918 hasAuthorship W2912776918A5050468802 @default.
- W2912776918 hasAuthorship W2912776918A5055212193 @default.
- W2912776918 hasAuthorship W2912776918A5069631984 @default.
- W2912776918 hasAuthorship W2912776918A5070444406 @default.
- W2912776918 hasAuthorship W2912776918A5070643359 @default.
- W2912776918 hasAuthorship W2912776918A5082832235 @default.
- W2912776918 hasConcept C121608353 @default.
- W2912776918 hasConcept C126322002 @default.
- W2912776918 hasConcept C141071460 @default.
- W2912776918 hasConcept C143998085 @default.
- W2912776918 hasConcept C197934379 @default.
- W2912776918 hasConcept C203092338 @default.
- W2912776918 hasConcept C2776694085 @default.
- W2912776918 hasConcept C2777701055 @default.
- W2912776918 hasConcept C2779551604 @default.
- W2912776918 hasConcept C2780030458 @default.
- W2912776918 hasConcept C2780739268 @default.
- W2912776918 hasConcept C31760486 @default.
- W2912776918 hasConcept C535046627 @default.
- W2912776918 hasConcept C71924100 @default.
- W2912776918 hasConcept C90924648 @default.
- W2912776918 hasConceptScore W2912776918C121608353 @default.
- W2912776918 hasConceptScore W2912776918C126322002 @default.
- W2912776918 hasConceptScore W2912776918C141071460 @default.
- W2912776918 hasConceptScore W2912776918C143998085 @default.
- W2912776918 hasConceptScore W2912776918C197934379 @default.
- W2912776918 hasConceptScore W2912776918C203092338 @default.
- W2912776918 hasConceptScore W2912776918C2776694085 @default.
- W2912776918 hasConceptScore W2912776918C2777701055 @default.
- W2912776918 hasConceptScore W2912776918C2779551604 @default.
- W2912776918 hasConceptScore W2912776918C2780030458 @default.
- W2912776918 hasConceptScore W2912776918C2780739268 @default.
- W2912776918 hasConceptScore W2912776918C31760486 @default.
- W2912776918 hasConceptScore W2912776918C535046627 @default.
- W2912776918 hasConceptScore W2912776918C71924100 @default.
- W2912776918 hasConceptScore W2912776918C90924648 @default.
- W2912776918 hasIssue "4_suppl" @default.
- W2912776918 hasLocation W29127769181 @default.
- W2912776918 hasOpenAccess W2912776918 @default.
- W2912776918 hasPrimaryLocation W29127769181 @default.
- W2912776918 hasRelatedWork W2412250098 @default.
- W2912776918 hasRelatedWork W2912776918 @default.
- W2912776918 hasRelatedWork W2936810997 @default.
- W2912776918 hasRelatedWork W2942064441 @default.
- W2912776918 hasRelatedWork W3005347589 @default.
- W2912776918 hasRelatedWork W3124005738 @default.
- W2912776918 hasRelatedWork W4285492859 @default.
- W2912776918 hasRelatedWork W4286295234 @default.
- W2912776918 hasRelatedWork W4286297256 @default.
- W2912776918 hasRelatedWork W4293827132 @default.
- W2912776918 hasVolume "37" @default.
- W2912776918 isParatext "false" @default.
- W2912776918 isRetracted "false" @default.
- W2912776918 magId "2912776918" @default.
- W2912776918 workType "article" @default.